Frequently Asked Questions

SAFE SUGAR™ is a very-low-glycemic crystalline sweetener platform developed by Lathell Nutraceuticals. It is positioned as a next-generation ingredient technology designed for food manufacturing, institutional nutrition systems, and health-focused reformulation pathways.

The platform is not presented as a simple retail sweetener. It is structured as a scalable ingredient system intended for broader commercial deployment through manufacturing partnerships, institutional adoption, and strategic commercialization channels.

Conventional sugar is widely used because of its familiarity and functionality, but it is also associated with significant metabolic concerns when consumed at modern population scale. SAFE SUGAR™ is positioned as a very-low-glycemic alternative designed to preserve critical use-case relevance while supporting healthier metabolic outcomes.

The goal is not merely sweetness replacement. The broader objective is to support ingredient modernization in contexts where food systems, institutions, and manufacturers need safer alternatives that still align with practical deployment needs.

SAFE SUGAR™ is primarily positioned as a B2B ingredient platform. The company’s strategic focus centers on manufacturers, institutional buyers, public-health aligned pathways, procurement-aligned deployment, and large-scale food system applications.

Consumer-facing opportunities may exist later, but the current commercial logic emphasizes scale through business, institutional, and strategic partner channels rather than a retail-first model.

SAFE SUGAR™ is intended for broad application areas where sugar functionality and metabolic impact both matter. These may include:

• beverages
• bakery and packaged foods
• functional foods
• medical nutrition
• institutional meal systems
• public-health aligned food programs

The platform is designed to support future deployment across categories where manufacturers and institutions need safer ingredient solutions without moving away from scalable operating realities.

Yes. SAFE SUGAR™ is being structured with global deployment in mind. The platform is intended for licensing, procurement, institutional pathways, manufacturing alignment, and cross-border strategic commercialization where healthier ingredient systems may be adopted at scale.

The company’s broader strategy is built around the idea that metabolic-risk reduction and safer ingredient alternatives are globally relevant, not limited to one region or one category of buyer.

SAFE SUGAR™ is intended to be commercialized through structured pathways that may include licensing, manufacturing partnerships, pilot collaboration, institutional procurement alignment, and strategic distribution relationships.

This commercialization approach is designed to create leverage by using partner infrastructure to support manufacturing, evaluation, distribution, and institutional access at meaningful scale.

Yes. Lathell Nutraceuticals is open to licensing discussions with qualified strategic manufacturers, ingredient companies, and commercial partners whose capabilities align with the platform’s scale-oriented objectives.

Licensing may be relevant where a partner has the ability to support manufacturing, distribution, regional deployment, or category-specific commercialization.

• pilot collaboration
• strategic ingredient licensing
• manufacturing alignment
• regional commercialization pathways
• institutional deployment planning
• joint evaluation or validation discussions

The exact structure depends on the strategic fit, commercial seriousness, and alignment with the platform’s long-term positioning.

Because it allows a technology platform to move faster than a purely self-contained direct-sales model. Partner infrastructure can support manufacturing, evaluation, distribution, and institutional access at a scale that is difficult to build alone in early phases.

A well-structured licensing and partnership model also helps turn platform value into practical deployment pathways.

Lathell Technology Platforms refers to the company’s broader integrated ecosystem of commercial, technical, and future-facing innovations. This includes ingredient platforms such as SAFE SUGAR™, physiological intelligence platforms such as OMNIPHYX™, and additional concepts or systems aligned with metabolic health, biosignal interpretation, diagnostics, and scalable health technology directions.

OMNIPHYX™ is a physiological intelligence platform positioned around human biosignal analysis, future monitoring logic, and advanced health-technology interpretation systems.

On the site, OMNIPHYX™ should be understood as an advanced platform within the ecosystem, while SAFE SUGAR™ remains the lead immediate commercial ingredient platform.

Because the site is intended to communicate both current commercial focus and broader innovation capacity. SAFE SUGAR™ demonstrates immediate commercialization potential in ingredient systems, while OMNIPHYX™ signals a wider technology vision around physiological intelligence and future health platforms.